Technical Articles

A systematic review of ActRIIA: extracellular ligand-binding domain, constitutively active intracellular kinase, ALK4 recruitment and SMAD2/3 phosphorylation. Covers physiological contexts from FSH rhythm in the pituitary to osteoclast-osteoblast bal

ActRIIA (ACVR2A) differs from its famous sibling ActRIIB by one letter, yet its fate diverged: outside the muscle spotlight it grew into a main line in bone metabolism and reproductive endocrine research. This article dissects the dual identity of Ac

ActRIIB (Activin Type IIB Receptor) and ACTRIIA (Activin Type IIA Receptor) are structurally similar transmembrane receptors belonging to the TGF-β receptor superfamily. They collectively function to receive extracellular "growth regulatory signals," yet exhibit key distinctions in their physiological roles and their value as drug targets.

ALK4 and ActRIIB are a functionally coupled pair of type I and type II transmembrane serine/threonine kinase receptors within the transforming growth factor-beta (TGF-β) superfamily signaling pathway. ActRIIB, as the type II receptor, features an extracellular domain that binds with high affinity to various ligands, including activin, GDF8 (myostatin), and GDF11, and possesses constitutive kinase activity. In contrast, ALK4, as the type I receptor, is strictly dependent on the type II receptor for its activation. Together, in the presence of ligand, they form a stable heterotetrameric signal transduction complex.